Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 8|浏览45

暂无评分

摘要

Adavosertib monotherapy demonstrates a manageable toxicity profile and promising clinical activity in refractory solid tumors harboring amplification, especially in epithelial ovarian cancer. Further study of adavosertib, alone or in combination with other therapeutic agents, in -amplified epithelial ovarian cancer is warranted.

查看译文

关键词

wee1 inhibitor adavosertib,refractory solid tumors harboring,solid tumors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要